- Transgene and ProBioGen partner to advance manufacturing for personalised cancer vaccines.
- AGE1.CR.pIX cell line to be utilised in Transgene’s myvac platform for improved vaccine production.
Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a CDMO in biologics, vaccines and viral vectors have entered a licensing agreement to advance manufacturing capabilities for personalised cancer vaccines using ProBioGen’s AGE1.CR.pIX suspension cell line. The collaboration aims to enhance productivity and scalability within Transgene’s myvac platform, supporting the production of tailored cancer immunotherapies.
The AGE1.CR.pIX cell line, developed by ProBioGen, has demonstrated high yield, scalability, and cost-effectiveness in various clinical trials, making it well-suited for large-scale, industrial manufacturing processes. This technology also offers robust growth and genetic stability, providing a reliable foundation for the production of individualised therapies.
“We are delighted to embark on this collaborative journey with ProBioGen,” commented Dr. Alessandro Riva, CEO of Transgene. “The AGE1.CR.pIX suspension cell line represents a significant addition to expand our manufacturing processes, allowing us to bring tailored, patient-specific therapies to a broader patient base.”
Dr. Volker Sandig, CSO of ProBioGen, echoed this sentiment, noting that the partnership “holds immense potential to impact the personalised vaccine space and offer new treatment options for cancer patients.”
Overview of outsourcing trends 
